180 related articles for article (PubMed ID: 26460615)
21. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
[TBL] [Abstract][Full Text] [Related]
22. The microenvironment induces collective migration in
D'Antongiovanni V; Martinelli S; Richter S; Canu L; Guasti D; Mello T; Romagnoli P; Pacak K; Eisenhofer G; Mannelli M; Rapizzi E
Endocr Relat Cancer; 2017 Oct; 24(10):555-564. PubMed ID: 28830936
[TBL] [Abstract][Full Text] [Related]
23. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.
Brouwers FM; Eisenhofer G; Tao JJ; Kant JA; Adams KT; Linehan WM; Pacak K
J Clin Endocrinol Metab; 2006 Nov; 91(11):4505-9. PubMed ID: 16912137
[TBL] [Abstract][Full Text] [Related]
24. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
[TBL] [Abstract][Full Text] [Related]
26. SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism.
Martinelli S; Riverso M; Mello T; Amore F; Parri M; Simeone I; Mannelli M; Maggi M; Rapizzi E
Mol Cell Endocrinol; 2022 May; 547():111594. PubMed ID: 35149119
[TBL] [Abstract][Full Text] [Related]
27. Structural and functional consequences of succinate dehydrogenase subunit B mutations.
Kim E; Rath EM; Tsang VH; Duff AP; Robinson BG; Church WB; Benn DE; Dwight T; Clifton-Bligh RJ
Endocr Relat Cancer; 2015 Jun; 22(3):387-97. PubMed ID: 25972245
[TBL] [Abstract][Full Text] [Related]
28. The occurrence of SDHB gene mutations in pheochromocytoma.
Van Nederveen FH; Dinjens WN; Korpershoek E; De Krijger RR
Ann N Y Acad Sci; 2006 Aug; 1073():177-82. PubMed ID: 17102084
[TBL] [Abstract][Full Text] [Related]
29. TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition.
Morin A; Goncalves J; Moog S; Castro-Vega LJ; Job S; Buffet A; Fontenille MJ; Woszczyk J; Gimenez-Roqueplo AP; Letouzé E; Favier J
Cell Rep; 2020 Mar; 30(13):4551-4566.e7. PubMed ID: 32234487
[TBL] [Abstract][Full Text] [Related]
30. Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot?
Cascón A; Montero-Conde C; Ruiz-Llorente S; Mercadillo F; Letón R; Rodríguez-Antona C; Martínez-Delgado B; Delgado M; Díez A; Rovira A; Díaz JA; Robledo M
Genes Chromosomes Cancer; 2006 Mar; 45(3):213-9. PubMed ID: 16258955
[TBL] [Abstract][Full Text] [Related]
31. Novel germline mutations in the SDHB and SDHD genes in Japanese pheochromocytomas.
Isobe K; Minowada S; Tatsuno I; Suzukawa K; Nissato S; Nanmoku T; Hara H; Yashiro T; Kawakami Y; Takekoshi K
Horm Res; 2007; 68(2):68-71. PubMed ID: 17308434
[TBL] [Abstract][Full Text] [Related]
32. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
[TBL] [Abstract][Full Text] [Related]
33. SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.
Blank A; Schmitt AM; Korpershoek E; van Nederveen F; Rudolph T; Weber N; Strebel RT; de Krijger R; Komminoth P; Perren A
Endocr Relat Cancer; 2010 Dec; 17(4):919-28. PubMed ID: 20702724
[TBL] [Abstract][Full Text] [Related]
34. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
Matro J; Giubellino A; Pacak K
Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
[TBL] [Abstract][Full Text] [Related]
35. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
36. Identification of succinate dehydrogenase-deficient bladder paragangliomas.
Mason EF; Sadow PM; Wagner AJ; Remillard SP; Flood TA; Belanger EC; Hornick JL; Barletta JA
Am J Surg Pathol; 2013 Oct; 37(10):1612-8. PubMed ID: 23797725
[TBL] [Abstract][Full Text] [Related]
37. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
38. Targeting NAD
Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
[No Abstract] [Full Text] [Related]
39. Succinate Mediates Tumorigenic Effects
Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
Astuti D; Hart-Holden N; Latif F; Lalloo F; Black GC; Lim C; Moran A; Grossman AB; Hodgson SV; Freemont A; Ramsden R; Eng C; Evans DG; Maher ER
Clin Endocrinol (Oxf); 2003 Dec; 59(6):728-33. PubMed ID: 14974914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
